Taxanes in hormone-refractory prostate cancer.
Kang
M H
MH
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Figg
W D
WD
Dahut
W
W
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D006728:Hormones; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine; D017239:Paclitaxel